Merck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA® Met Endpoints of Recurrence-Free Survival (RFS) and Distant Metastasis-Free Survival (DMFS) in Patients Wi

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/18/2026

1. SPY
2. XENE
3. NUE
4. HUBS
5. RTB
6. ONON
7. AAPL
8. ACN
9. AZN
10. SPCX

Go back to Merck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA® Met Endpoints of Recurrence-Free Survival (RFS) and Distant Metastasis-Free Survival (DMFS) in Patients Wi
Merck & Co. (NYSE: MRK) Delayed: 146.87 -0.28 (0.19%)
Previous Close $147.15    52 Week High $65.46 
Open $147.08    52 Week Low $47.97 
Day High $147.84    P/E 99.91 
Day Low $145.74    EPS $1.47 
Volume 31,159,364       

Marina Biotech, Inc. (NASDAQ: MRNA) Delayed: 154.04 -4.03 (2.55%)
Previous Close $158.07    52 Week High $0.52 
Open $158.35    52 Week Low $0.08 
Day High $159.79    P/E N/A 
Day Low $150.29    EPS $-3.80 
Volume 20,237,194